![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 40, 28329-28334, October 1, 1999
From the Human natural killer cells and a
subset of T cells express a repertoire of killer cell immunoglobulin
receptors (KIRs) that recognize major histocompatibility complex (MHC)
class I molecules. KIRs and T cell receptors (TCRs) bind in a
peptide-dependent manner to overlapping regions of
peptide-MHC class I complexes. KIRs with two immunoglobulin domains
(KIR2Ds) recognize distinct subsets of HLA-C alleles. Here we use
surface plasmon resonance to study the binding of soluble forms of
KIR2DL1 and KIR2DL3 to several peptide-HLA-Cw7 complexes. KIR2DL3 bound
to the HLA-Cw7 allele presenting the peptide RYRPGTVAL with a 1:1
stoichiometry and an affinity (Kd ~7
µM at 25 °C) within the range of values measured for
other cell-cell recognition molecules, including the TCR. Although
KIR2DL1 is reported not to recognize the HLA-Cw7 allele in functional
assays, it bound RYRPGTVAL/HLA-Cw7, albeit with a 10-20-fold lower
affinity. TCR/peptide-MHC interactions are characterized by
comparatively slow kinetics and unfavorable entropic changes (Willcox,
B. E., Gao, G. F., Wyer, J. R., Ladbury, J. E.,
Bell, J. I., Jakobsen, B. K., and van der Merwe, P. A. (1999) Immunity 10, 357-365), suggesting that binding is
accompanied by conformational adjustments. In contrast, we show that
KIR2DL3 binds RYRPGTVAL/HLA-Cw7 with fast kinetics and a favorable
binding entropy, consistent with rigid body association. These results indicate that KIR/peptide-MHC class I interactions have properties typical of other cell-cell recognition molecules, and they highlight the unusual nature of TCR/peptide-MHC recognition.
NK1 cells and CD8 T
lymphocytes have complementary roles in the cellular immune response.
Whereas CD8 lymphocytes kill cells presenting non-self peptides on MHC
class I molecules, NK cells kill cells deficient in MHC class I
molecules (1-3). In so doing they make it difficult for intracellular
pathogens to evade the immune response by interfering with the
expression of MHC class I molecules. It is thought that NK cells are
stimulated to kill somatic cells by ligation of one or more activatory
receptors but are held in check if inhibitory receptors are able to
bind MHC class I molecules on these cells. In humans a family of killer cell Ig receptors (KIRs) has been identified on NK cells, and a subset
of T cells, that bind to MHC class I molecules (4). The KIR genes are
clustered on chromosome 19q13.4 (5, 6). The precise number (~10)
appears to vary between individuals (7). These characteristics, and the
absence of homologous genes in rodents, suggest that the KIR gene
family evolved fairly recently, perhaps driven by the rapid evolution
of MHC class I molecules (8).
KIRs have either two (KIR2D) or three (KIR3D) Ig domains in the
extracellular region (9). They can be further grouped according to
whether they have a short (e.g. KIR2DS) or long
(e.g. KIR2DL) cytoplasmic tail (9). The long cytoplasmic
tails contain immunoreceptor tyrosine-based inhibitory motifs and
transduce inhibitory signals (10). In contrast, the short cytoplasmic
tails mediate association with DAP12 (11), which contains
immunoreceptor tyrosine-based activation motifs and transduces
activatory signals.
The KIR2D receptors bind HLA-C alleles, whereas KIR3D receptors bind
HLA-A and -B alleles (12, 13). Like the TCR, KIRs bind to the
peptide-presenting platform on MHC class I molecules (14, 15). The
KIR2D-binding site on HLA-C includes residues in the carboxyl-terminal
half of the Recently Valés-Gómez et al. (23, 24) used
surface plasmon resonance to measure the affinity of KIR2DL1 and
KIR2DL3 binding HLA-Cw6-peptide and HLA-Cw7-peptide complexes,
respectively. The dissociation rate constant
(koff) was also estimated, but the association
rate constant (kon) could not be measured
directly (23, 24). We extend this study by providing more precise
kinetic measurements of the KIR2DL3/peptide-HLA-Cw7 interaction,
obtaining thermodynamic data, and determining the stoichiometry of the
interaction. We also use affinity measurements to quantitate the
effects of the peptide on the binding affinity and the degree of
cross-reactivity between KIR2DL1 and HLA-Cw7. We find that KIR2DL3
binds peptide-HLA-Cw7 with a 1:1 stoichiometry and with thermodynamic
and kinetic properties very similar to other cell-cell
recognition molecules. These properties differ from those
reported for TCR/peptide-MHC interactions, underlining the unusual
nature of TCR recognition.
Production of Soluble Forms of KIR2DL1 and KIR2DL3--
DNA
encoding the extracellular portions (residues 1-224) of KIR2DL1 and
KIR2DL3 were amplified from cDNA, obtained as described previously
(6), using 5'-G GCC ATG GCA CAT GAG GGA GTC CAC-3' as forward primer
and 5'-C AGC GGC CGC GTG CAG GTG TCG GGG GTT ACC-3' as reverse primer.
The resultant fragments were digested with the restriction enzymes
NcoI and NotI and ligated into a derivative of
pGEM2 (Promega). The final construct encodes, in tandem, the
Shine-Dalgano and signal peptide sequence of pelB, the extracellular
portion of KIR2DL1 or KIR2DL3, a c-myc epitope and an
oligohistidine tag (HHHHHH), all between the HindIII and EcoRI restriction sites of pGEM2 and under the control of a
T7 promoter. The resulting expression plasmid was designated pKMATHNK1 or -2. Escherichia coli strain BL21(DE3)pLysS cells
(Novagen) harboring pKMATHNK1 or -2 were grown at 37 °C in 2× YT
medium containing ampicillin (100 µg/ml) and chloramphenicol (34 µg/ml), induced with 0.1 mM
isopropyl-
A second expression system was established to increase the yield of
KIR2Ds. The genes of the extracellular portions (residues 1-224) of
KIR2DL1 and KIR2DL3 were amplified using 5'-GGAACATATGCACGAGGGAG TCCACAG-3' as forward primer and 5'-CGGAGGCTTACTAATGC
AGGTGTCTGGGGTTAC-3' as reverse primer. The resultant fragments were
digested with the restriction enzymes NdeI and
HindIII and ligated into pGMT7 (25), creating the plasmids
pGMNK1 and pGMNK2 encoding KIR2DL1 and KIR2DL3, respectively. The
plasmids were expressed in the E. coli strain BL21(DE3)
pLysS. Recombinant proteins, which accumulate as insoluble aggregates
in inclusion bodies, were refolded and purified by the method of Reid
et al. (25). In some cases proteins were further purified by
ion exchange chromatography (ResourceQ, Amersham Pharmacia Biotech).
Production of Soluble HLA Molecules--
A DNA fragment encoding
the extracellular portion of HLA-Cw0702 heavy chain (residues 1-276)
was amplified from cDNA kindly provided by Dr. H. Wang,
using 5'-CCCACACATATGGGATCCCACTCCATG AGGTATTTCGAC-3' as forward primer
and 5'-CCCACAAAGCTTCTATCATGGCTCCCAGCTCAGGGTGAGGGG-3' as reverse
primer. The resultant fragment was digested with the restriction
enzymes NdeI and HindIII and ligated into pGMT7
(25). HLA-Cw7 was recovered from inclusion bodies, refolded with
peptide and Surface Plasmon Resonance--
Surface plasmon resonance
experiments were performed using a BIAcoreTM 2000 (BIAcore
AB, St. Albans, UK). All the experiments were performed at 25 °C
unless otherwise indicated using HBS-EP (10 mM Hepes (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, and 0.005%
Surfactant P20) as running buffer when using CM5 sensor chips and HBS-P
(HBS-EP without EDTA) when using Ni-NTA sensor chips (BIAcore AB).
Biotinylated proteins were immobilized via streptavidin, which was
covalently coupled to CM5 research grade sensor chips as described
previously (28). Proteins with oligohistidine tags (sKIR2DL3H and
sKIR2DL1H) were immobilized onto Ni-NTA sensor chips (BIAcore AB).
Ni-NTA surfaces were regenerated by injection of 0.35 M
EDTA (pH 8.3) for 1 min to elute bound protein followed by 0.5 M NiCl2 for 1 min to recharge the NTA with nickel.
Kinetic constants were derived using the curve-fitting facility of the
BIAevaluation program (version 3.0, BIAcore) that deploys the
Marquardt-Levenberg algorithm. Rate equations were derived from the
simple 1:1 Langmuir binding model (A + B Gel Filtration--
sKIR2DL3 (60 µl at 1 mM) and
HLA-Cw7-DS11 (40 µl at 1 mM) were mixed and incubated for
1 h at room temperature before separation by fast protein liquid
chromatography on a Superdex 200 (Amersham Pharmacia Biotech) in 20 mM Tris-Cl (pH 8) at a flow rate of 0.4 ml/min.
Stoichiometry and Peptide Dependence of sKIR2DL3 Binding to
HLA-Cw7--
Soluble MHC class I heavy chains were expressed in
bacteria and refolded in vitro together with peptide and
Binding of KIR constructs was analyzed by surface plasmon resonance,
which measures the changes in refractive index near a sensor surface
(31). sKIR2DL3 was injected through 4 flow cells containing sensor
surfaces to which different peptide-MHC class I complexes had been
immobilized using their biotin tag (Fig. 1A, solid bar). A
"background" response (measured in response units) is seen in the
negative control HLA-A2 flow cell, a consequence of the high
concentration, and therefore high refractive index, of injected
sKIR2DL3 sample. However, a greater response is seen with injection
over HLA-Cw7 complexed with the DS11 peptide, indicating binding (Fig.
1A). sKIR2DL3 bound at a much lower level to HLA-Cw7 complexed with the DS12 peptide and did not bind at all to the HLA-Cw7-DS10 complex (Fig. 1A).
In order to assess the stoichiometry of binding, HLA-Cw7-DS11 and
sKIR2DL3 were mixed together, with a molar excess of sKIR2DL3 (1:1.5),
and then fractionated by size exclusion chromatography (Fig.
1B). The elution position of the complex (~74 kDa,
calculated Mr 69,304) is consistent with the
presence of one sKIR2DL3 molecule and one HLA-Cw7-DS11 molecule.
Furthermore, whereas free sKIR2DL3 was present, no free HLA-Cw7-DS11
was detected, indicating that there was an excess of the sKIR2DL3 (Fig.
1B). Taken together, these data indicate that sKIR2DL3 binds
HLA-Cw7-DS11 with a 1:1 stoichiometry.
Affinity of sKIR2DL3 and sKIR2DL1 Binding to HLA-Cw7
Peptide--
The affinity of sKIR2Ds binding to peptide-MHC molecules
was measured by equilibrium binding analysis on the BIAcore. A range of
concentrations of sKIR2DL3 (Fig.
2A) was injected through flow cells with HLA-Cw7-DS11 or a control peptide-MHC class I complex immobilized. The binding response at each concentration was calculated by subtracting the equilibrium response measured in the control flow
cell from response in the HLA-Cw7-DS11 flow cell. Conventional (Fig.
2B) and Scatchard (Fig. 2B, inset) plots of these
binding data indicate that the interaction conforms to a simple 1:1
(Langmuir) binding model with a Kd of ~9
µM. The results of several experiments are summarized in
Table I. Other soluble recombinant forms
of sKIR2DL3 bound immobilized HLA-Cw7-DS11 with a similar affinity
(data not shown). These included sKIR2DL3H and a truncated version of
sKIR2DL3 (comprising amino acids 1-200) which lacked the
membrane-proximal stalk region. A similar affinity was measured in the
reverse orientation, with sKIR2DL3H immobilized to a
Ni2+-NTA sensor chip via its oligohistidine tag, and
HLA-Cw7-DS11 in solution (Table I).
The weak interaction between sKIR2DL3 and HLA-Cw7-DS12 peptide (Fig.
1A) was confirmed by affinity analysis (data not shown). sKIR2DL3 bound to HLA-Cw7-DS12 with an affinity (Kd
~108 µM) ~12-fold lower than its affinity for
HLA-Cw7-DS11 (Fig. 2B). This very low affinity was confirmed
in the reverse orientation, with sKIR2DL3H immobilized and HLA-Cw7/DS12
in solution.
sKIR2DL1 also bound to HLA-Cw7-DS11, albeit with a 10-15-fold lower
affinity than sKIR2DL3 (Fig. 2B and Table I). This lower affinity was largely a consequence of a faster
koff (data not shown), indicating that it is not
a consequence of low sKIR2DL1 activity. No binding was detected when
high concentrations (up to 3 mM) of sKIR2DL1 and sKIR2DL3
were injected over several other classical (HLA-A2 and -B35) and
non-classical (HLA-E and -G1) MHC class I molecules (Table I).
Binding Kinetics--
Although binding and dissociation were very
fast, it was possible to analyze both the association and dissociation
phases of binding (Fig. 3). Global
fitting with mono-exponential rate equations derived from the simple
1:1 Langmuir binding model produced reasonable fits, yielding a
kon of 1.6 × 105
M
Because recent studies have shown that the kinetics of TCR binding to
peptide-MHC are strongly temperature-dependent (32), we
analyzed the temperature dependence of the KIR/peptide-MHC interaction
(Fig. 3B). The koff of a
TCR/peptide-MHC interaction increased ~40-fold as the temperature was
raised from 5 to 25 °C (32). In contrast, the
koff of the sKIR2DL3/HLA-Cw7-DS11 interaction
increased a modest ~4-fold over the same temperature range (Fig.
3B). Arrhenius plots yield an activation energy of 13 kcal·mol Thermodynamic Analysis--
The enthalpy change ( Peptide Dependence--
Although several studies have demonstrated
that NK cell recognition is dependent on the peptide as well as the MHC
on target cells, no studies have measured directly the effect of
peptide on the affinity of a KIR for a peptide-MHC class I complex.
Consistent with functional (21) and binding (18) assays, we found that the affinity of sKIR2DL3 binding to HLA-Cw7-peptide was dramatically affected by the nature of the peptide (Fig. 1A and Table I). sKIR2DL3 bound to HLA-Cw7-DS11, -DS12, and -DS10 with a
Kd ~7 µM, ~115 µM,
and >3 mM, respectively (Table I). In agreement with this,
Valés-Gómez et al. (18) found that sKIR2DL3
bound to HLA-Cw7-DS11 but not to HLA-Cw7-DS10. Interestingly,
Mandelboim et al. (21) showed that killing by several NK
clones specific for group 2 HLA-C alleles was inhibited when target
cells expressed HLA-Cw7 loaded with the DS12 peptide. This suggests
that affinities as low as Kd ~115 µM
are sufficient to mediate inhibition. Paradoxically, however,
HLA-Cw7-loaded with DS10 peptide (KYFDEHYEY), which we and others (18)
show does not bind to sKIR3DL3, was a better inhibitor of most of these
NK clones than HLA-Cw7-DS12 (21). In only one of the clones studied
(dp10.7) did the functional inhibition data (21) correlate with the
direct binding data. A likely explanation for these results is that
these NK clones express multiple KIRs, highlighting the importance of
using purified KIRs to analyze the binding specificity.
Stoichiometry--
Based on the structural similarity between
KIR2DL1 and hematopoietic receptors (e.g. growth hormone
receptor, which binds growth hormone with a 2:1 stoichiometry), Fan
et al. (34) proposed that a single peptide-MHC class I
complex might bind to two KIR molecules, providing a possible mechanism
for signaling. However, our results suggest that sKIR2DL3 binds to
soluble HLA-Cw7-DS11 in a 1:1 complex. First, free sKIR2DL3 but no free
HLA-Cw7-DS11 is detected when sKIR2DL3 and HLA-Cw7-DS11 are mixed in a
ratio 1.5:1. Second, the sKIR2DL3/HLA-Cw7-DS11 complex migrated on gel filtration at the position expected for a 1:1 complex. Third, SDS-polyacrylamide gel electrophoresis of the peak complex indicated that there were equimolar amounts of sKIR2DL3 and HLA-Cw7 heavy chain
(data not shown). Finally, the standard Langmuir 1:1 binding model fits
very well to the equilibrium binding and kinetic data. We cannot
exclude a second sKIR2DL3 site on HLA-Cw7 with a much lower affinity
(e.g. Kd >200 µM).
However, such a second site would need to achieve a much higher
"physiological" affinity at the cell/cell interface in order to
contribute to KIR2DL3 binding (35).
The 1:1 binding stoichiometry suggests that, despite some structural
similarities between KIRs and hematopoietic receptors, they do not bind
their ligands in the equivalent manner. Indeed, comparison of the
recently determined KIR2DL3 crystal structure with Ig superfamily and
fibronectin type III domains indicates that KIRs bear a closer
resemblance to Ig domains than to the fibronectin type III domains of
hematopoietic receptors (30).
Affinity, Kinetics, and Thermodynamics--
The affinity measured
here between soluble forms of KIR2DL3 and the HLA-Cw7-DS11 peptide-MHC
complex agrees well with the affinity measured independently by
Valés-Gómez et al. (24) (Kd
~9 µM) for sKIR2DL3 binding HLA-Cw7-DS11.
Valés-Gómez et al. (24) measured a similar
affinity (Kd ~10 µM) between soluble
forms of sKIR2DL1 and HLA-Cw6-peptide. This consistency between
completely independent studies suggests that these affinity measurements are likely to be correct.
These affinities are well within the range of affinities measured for
many other cell-cell recognition molecules, including TCR/peptide-MHC
interactions (Table III). However
TCR/peptide-MHC interactions differ from other cell-cell molecule
interactions in that low affinity of TCR binding is a consequence of a
relatively slow kon rather than a fast
koff (32, 36). Unlike Valés-Gómez et al. (23, 24), we were able to obtain precise estimates of
the binding kinetics of the sKIR2DL3/HLA-Cw7-DS11 interaction. This
revealed that, in contrast to TCR/peptide-MHC interactions, the low
affinity is a consequence of a faster koff,
whereas the kon is unremarkable, being typical
of other cell surface protein/protein interactions (Table III).
Furthermore, the KIR binding kinetics did not show the strong
temperature dependence observed with TCR binding.
Further differences between KIR/peptide-MHC and TCR/peptide-MHC
interactions were evident in thermodynamic studies. Unlike TCR binding,
which is characterized by large, unfavorable entropic changes
compensated for by even larger favorable enthalpic changes, KIR binding
is driven by favorable entropic and enthalpic changes at 25 °C (Fig.
4B). The latter thermodynamic characteristics are typical of
protein/protein interactions (Fig. 4B) including low affinity interactions between cell-cell recognition molecules, such as
the CD2/CD48
interaction.2
A key finding in this study is that TCRs and KIRs, although recognizing
overlapping portions of peptide-MHC class I molecules, bind with very
different kinetic and thermodynamic properties. The KIR/peptide-MHC
interaction has binding properties consistent with rigid body
association, whereas TCR binding has been shown to require
conformational adjustments (37) and is likely to be accompanied by a
reduction in conformational flexibility (32). The difference in the
binding properties of KIRs and TCRs for very similar ligands supports
the suggestion the TCR and not the peptide-MHC are the primary source
of conformational flexibility. We have proposed that these binding
properties arise from the structure of TCR antigen-binding sites and
the unique manner in which they are generated (32). First, these
antigen-binding sites are formed from peptide loops exclusively, 3-4
from each of the two V domains. Second, the loops have highly variable
primary structures and are combined in a semi-random manner. Third,
because TCR antigen-binding sites are not germline-encoded and cannot be inherited, they are denied the opportunity, available to other ligand-binding proteins, to acquire a more stable tertiary
structure during the course of evolution.
Cross-reactivity of KIR2DL1 with HLA-Cw7--
Although
KIR2DL molecules are grouped according to whether they bind to group 1 (KIR2DL1) or group 2 (KIR2DL2 and -L3) HLA-C alleles, recent data
suggest that there is some cross-reactivity. KIR2DL2 and -L3 have been
shown to bind to, and mediate inhibition by, group 1 HLA-C alleles. We
show here that KIR2DL1 can also cross-react with a group 2 HLA-C
allele. The affinity of the latter interaction is ~10-fold lower than
the affinity of sKIR2DL1 and sKIR2DL2 or 3 molecules for group 1 and
group 2 HLA-C alleles, respectively. Interestingly,
Valés-Gómes et al. (18) also found some evidence
for weak binding of sKIR2DL1 and HLA-Cw7-peptide. Whether such
cross-reactivity is functionally significant remains to be demonstrated.
Conclusion--
We show here that a KIR binds peptide-MHC with a
1:1 stoichiometry and that the thermodynamic and kinetic features of
this interaction are typical of cell/cell recognition molecules and consistent with rigid body association. This contrasts with
TCR/peptide-MHC interactions, which have thermodynamic and kinetic
properties more consistent with conformational adjustments at the
binding interface. These differences draw attention to some unusual
features of antigen recognition by TCRs and suggest that there are
fundamental differences in the signal transduction mechanisms that
follow KIR and TCR ligation of peptide-MHC.
We thank I. Kumagai, M. Matsushima,
and K. Tsumoto for their advice and helpful discussion; B. Willcox, C. O'Callaghan, B. Jakobsen, A. McMichael, and J. Bell for
MHC class I molecules; and H. Wang for providing a cDNA of
HLA-Cw0702. We are grateful to our colleagues in the Japanese Red Cross
Blood Center for their encouragement. The Oxford Center for Molecular
Sciences is supported by the BBSRC, MRC, and EPSRC.
*
This work was supported in part by a Grant-in-aid for
Scientific Research on Priority Areas 2782 from the Ministry of
Education, Science, and Culture of Japan.The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Supported in part by a JSPS Research Fellowship for Young
Scientists and by a Human Frontier Science Program long term
fellowship. To whom correspondence should be addressed: Structural
Biology, Wellcome Trust Centre for Human Genetics, Roosevelt Dr.,
Headington, Oxford OX3 7BN, UK. Tel.: 44-1865-287550; Fax:
+44-1865-287547; E-mail: katsumi@strubi.ox.ac.uk.
§§
Supported by the Royal Society. To whom correspondence should be
addressed: Structural Biology, Wellcome Trust Centre for Human
Genetics, Roosevelt Dr., Headington, Oxford OX3 7BN, UK. Tel.:
44-1865-287559; Fax: 44-1865-287547; E-mail:
yvonne@strubi.ox.ac.uk.
2
J. Ladbury, P. A. van der Merwe, and
S. J. Davis, unpublished data.
The abbreviations used are:
NK, natural killer;
KIR, killer cell immunoglobulin receptor;
KIR2D, KIR with 2 Ig domains;
MHC, major histocompatibility complex;
TCR, T cell receptor;
Ni-NTA, nickel charged nitrilotriacetic acid.
Killer Cell Immunoglobulin Receptors and T Cell Receptors Bind
Peptide-Major Histocompatibility Complex Class I with Distinct
Thermodynamic and Kinetic Properties*
§¶,
,
,
,
,
**
,
**§§, and
¶¶
Structural Biology, Wellcome Trust Centre
for Human Genetics, Roosevelt Drive, Headington, Oxford OX3 7BN,
United Kingdom, § Japanese Red Cross Central Blood Center,
4-3-1 Hiro-o, Shibuya-ku, Tokyo 120, Japan,
MRC Human
Immunology Unit,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1-helix (residues 73, 76 and 80) and the adjacent
-sheet (residue 90). KIR2DL1 binds preferentially to group 1 HLA-C
alleles (Cw2, Cw4, Cw5, Cw6, Cw15), which have Lys at position 80, whereas KIR2DL2 and KIR2DL3 bind preferentially to group 2 HLA-C
alleles (Cw1, Cw3, Cw7, Cw8), which have Asn at position 80. However,
there appears to be some cross-reactivity between these groups
(16-18). KIR recognition of peptide-MHC class I has been shown to
depend to some extent on the peptide presented on the MHC molecule (17,
19-22). These observations suggest that a single KIR will bind
different peptide-MHC complexes with different affinities, raising the
question as to what the affinity and/or kinetic threshold is for
functional recognition?
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-D-thiogalactopyranoside in logarithmic phase
(A280 0.6-0.8), and then incubated for 17 h at 27 °C. Recombinant protein secreted into the periplasmic space
and media (yield approximately 0.2 mg/l) were concentrated by ammonium
sulfate precipitation and purified by metal-chelate affinity
chromatography (Ni-NTA superflow, Qiagen) followed by ion exchange
chromatography (MonoQ, Amersham Pharmacia Biotech).
2-microglobulin, and purified using the
method of Reid et al. (25). One of the following peptides
was used: KYFDEHYEY (DS-10), RYRPGTVAL (DS11), or NKADVILKY (DS12).
Biotinylated HLA-Cw7 was prepared by refolding in the presence of
biotinylated
2-microglobulin (26, 27). HLA-A2 (with
peptide ILKEPVHGV), HLA-B35 (TPEGIIPTL), HLA-E (VMAPRTVLL), and HLA-G1
(RIIPRHLQL) were produced in the same way.
AB). Other curve fitting
was performed in Origin version 3 (MicroCal). Affinity constants were
derived by Scatchard analysis or by non-linear curve fitting of the
standard Langmuir binding isotherm. Thermodynamic data were obtained by
fitting to the data in Fig. 4A the non-linear form of the
van't Hoff Equation (29),
where T is the temperature in Kelvin (K);
To is an arbitrary reference temperature (e.g.
298.15 K);
(Eq. 1)
G0 is the standard free energy of
binding at T (kcal·mol
1) and is calculated
from the Kd;
HTo is the enthalpy change upon binding at To
(kcal·mol
1);
S0To is
the standard state entropy change upon binding at To
(kcal·mol
1), and
Cp is the
specific heat capacity (kcal·mol
1·K
1),
and is assumed to be temperature-independent.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2-microglobulin (see "Experimental Procedures").
Biotinylated peptide-MHC class I complexes were produced by refolding
with chemically biotinylated
2-microglobulin (28).
Soluble forms of KIR2D molecules were also expressed in bacteria,
either with (sKIR2DL1H and sKIR2DL3H) or without (sKIR2DL1 and
sKIR2DL3) carboxyl-terminal c-myc and oligohistidine tags
(see "Experimental Procedures"). sKIR2DL3H was used successfully
for an x-ray crystallographic structure determination (30), indicating
that it is correctly folded. Purified sKIRs migrated as monomers on
size exclusion chromatography (Fig.
1B and data not shown).

View larger version (19K):
[in a new window]
Fig. 1.
Peptide dependence and stoichiometry of
sKIR2DL3 binding to HLA-Cw7. A, sKIR2DL3 (106 µM) was injected at a flow rate of 10 µl/min
(solid bar) through flow cells with the indicated
peptide-MHC class I complex immobilized to the sensor surface. HLA-Cw7
was complexed with DS10, DS11, or DS12 peptides (see "Experimental
Procedures"). B, size exclusion chromatography of
sKIR2DL3/HLA-Cw7-DS11 complex. A 100-µl mixture of sKIR2DL3 (0.6 mM) and HLA-Cw7-DS11 (0.4 mM) was fractionated
on a Sephadex 200 column. The elution positions are shown of protein
molecular mass standards (in kDa). A calibration curve based on these
standards was used to estimate the Mr of
sKIR2DL3 and the sKIR2DL3-HLA-Cw7-DS11 complex. Also shown is the
expected elution position of free HLA-Cw7-DS11, which was determined on
a separate run (data not shown). RU, response units.

View larger version (31K):
[in a new window]
Fig. 2.
Affinity of KIR molecules binding to
immobilized HLA-Cw7-DS11. A, sKIR2DL3 was injected for
30 s at the indicated concentrations through flow cells with
HLA-Cw7. B, a plot of the equilibrium binding response of
sKIR2DL3 (
, derived from A) and sKIR2DL1 (
, raw data
not shown) versus concentration. The solid lines
represent direct non-linear fits of the 1:1 Langmuir binding isotherm
to the data, which yielded the indicated Kd values.
Inset, Scatchard plots of the same data are shown. The
solid lines are linear fits, which yielded
Kd estimates of 8 and 84 µM for
sKIR2DL3 and sKIR2DL1, respectively. RU, response
units.
Summary of affinity constants
1 s
1 and a
koff of 1.2 s
1 (Fig.
3A). The rate constants did not change significantly when the level of immobilized HLA-Cw7-DS11 varied 2-fold (Table
II), indicating that binding was not
substantially affected by mass transport or rebinding artifacts. The
excellent agreement between calculated Kd (Table II)
and the Kd determined by equilibrium binding (Table
I) further supports the notion that these kinetic constants are
correct.

View larger version (27K):
[in a new window]
Fig. 3.
Kinetic analysis of sKIR2DL3 binding to
HLA-Cw7-DS11. A, sKIR2DL3 was injected (solid
bar) at the indicated concentrations at high flow rate (50 µl·min
1) over HLA-C7-DS11 (1500 response units
(RU)). The traces shown have had their corresponding
background responses (obtained with injection over the HLA-A2 surface)
subtracted. Rate equations derived from the 1:1 Langmuir binding model
(A + B
AB) were fitted by numerical integration simultaneously to
the association and dissociation phases of all three injections
("global fitting"). Residual errors from the fits are shown in the
bottom panel. B, temperature dependence of
binding kinetics. sKIR2DL3 (10 µM) was injected
(solid bar) at 50 µl·min
1 over
HLA-Cw7-DS11 at the indicated temperatures. The responses observed with
injection of the same samples over HLA-A2-peptide have been subtracted.
To aid comparison the traces have been normalized so that maximum
binding at each temperature equals 100%. The
koff values, determined by fitting
mono-exponential decay curves (solid lines), were 0.2, 0.34, and 0.8 s
1 at 5, 15, and 25 °C, respectively.
Inset, Arrhenius plot of koff data
(KIR). Also shown is an Arrhenius plot of the
koff of the JM22z TCR dissociating from
HLA-A2-Flu peptide, taken from Ref. 32.
Summary of kinetic data
1 for sKIR2DL3/HLA-Cw7-DS11 dissociation (Fig.
3B, inset), far lower than the ~30 kcal·mol measured for
TCR/peptide-MHC dissociation (32).
H)
that accompanies KIR binding to peptide-MHC was estimated by van't
Hoff analysis, which involves measuring the dependence of affinity on
temperature (Fig. 4A). Because
the enthalpy and entropy vary with temperature, the non-linear form of
the van't Hoff equation was used (see "Experimental Procedures"). At 25 °C favorable enthalpic (
HvH ~
4.1
kcal·M
1) and entropic
(
T
S0 ~
3.1
kcal·M
1) changes contribute in
approximately equal measure to the binding energy
(
G0 ~
7.2
kcal·M
1). The heat capacity derived from
this fit (
Cp ~
100 cal·M
1), which is a measure of the
dependence of the binding enthalpy and entropy change on temperature,
is well within the range determined for other protein/protein
interactions (33). Similar values for
HvH and
T
S0 were obtained when using the
linear form of van't Hoff equation (data not shown), which assumes
that the enthalpy is temperature-independent.

View larger version (18K):
[in a new window]
Fig. 4.
A, thermodynamic analysis of sKIR2DL3
binding to HLA-Cw7-DS11. Measurement of enthalpy by van't Hoff
analysis (
HvH). Affinity constants for the
sKIR2DL3/HLA-Cw7-DS11 interaction were measured at several temperatures
(5-30 °C) and converted into the standard free energy of binding
(
G0). Values for the enthalpic
(
HvH) and standard entropic
(
T
S0) changes (at 25 °C) and
the specific heat capacity (
Cp) were derived by
fitting the non-linear form of the van't Hoff equation to these data
(see "Experimental Procedures"). B, comparison of
thermodynamic properties (at 25 °C) of several macromolecular
interactions. The values for protein/protein interactions (excluding
antibody/protein interactions) are the mean and S.E. of 30 calorimetric
determinations taken from Ref. 33. Data for TCR/peptide-MHC
interactions are the mean and range of two determinations, one of which
was by calorimetry (32).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Summary of affinity and kinetic data for lymphocyte cell-cell
recognition molecules
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Karre, K.,
Ljunggren, H. G.,
Piontek, G.,
and Kiessling, R.
(1986)
Nature
319,
675-678[CrossRef][Medline]
[Order article via Infotrieve]
2.
Ljunggren, H. G.,
and Karre, K.
(1990)
Immunol. Today
11,
237-244[CrossRef][Medline]
[Order article via Infotrieve]
3.
Liao, N. S.,
Bix, M.,
Zijlstra, M.,
Jaenisch, R.,
and Raulet, D.
(1991)
Science
253,
199-202 4.
Lanier, L. L.
(1997)
Immunity
6,
371-378[CrossRef][Medline]
[Order article via Infotrieve]
5.
Baker, E.,
D'Andrea, A.,
Phillips, J. H.,
Sutherland, G. R.,
and Lanier, L. L.
(1995)
Chromosome Res.
3,
511-512[CrossRef]
6.
Suto, Y.,
Maenaka, K.,
Yabe, T.,
Hirai, M.,
Tokunaga, K.,
Tadokoro, K.,
and Juji, T.
(1996)
Genomics
35,
270-272[CrossRef][Medline]
[Order article via Infotrieve]
7.
Suto, Y.,
Ishikawa, Y.,
Kasahara, M.,
Kasai, F.,
Yabe, T.,
Akaza, T.,
and Juji, T.
(1998)
Immunogenetics
48,
235-241[CrossRef][Medline]
[Order article via Infotrieve]
8.
Gumperz, J. E.,
and Parham, P.
(1995)
Nature
378,
245-248[CrossRef][Medline]
[Order article via Infotrieve]
9.
Selvakumar, A.,
Steffens, U.,
Palanisamy, N.,
Chaganti, R. S.,
and Dupont, B.
(1997)
Tissue Antigens
49,
564-573[Medline]
[Order article via Infotrieve]
10.
Lanier, L. L.
(1998)
Annu. Rev. Immunol.
16,
359-393[CrossRef][Medline]
[Order article via Infotrieve]
11.
Lanier, L. L.,
Corliss, B. C.,
Wu, J.,
Leong, C.,
and Phillips, J. H.
(1998)
Nature
391,
703-707[CrossRef][Medline]
[Order article via Infotrieve]
12.
Colonna, M.
(1996)
Curr. Opin. Immunol.
8,
101-107[CrossRef][Medline]
[Order article via Infotrieve]
13.
Lanier, L. L.,
and Phillips, J. H.
(1996)
Immunol. Today
17,
86-91[CrossRef][Medline]
[Order article via Infotrieve]
14.
Biassoni, R.,
Falco, M.,
Cambiaggi, A.,
Costa, P.,
Verdiani, S.,
Pende, D.,
Conte, R.,
Di Donato, C.,
Parham, P.,
and Moretta, L.
(1995)
J. Exp. Med.
182,
605-609 15.
Mandelboim, O.,
Reyburn, H. T.,
Sheu, E. G.,
Valés-Gómez, M.,
Davis, D. M.,
Pazmany, L.,
and Strominger, J. L.
(1997)
Immunity
6,
341-350[CrossRef][Medline]
[Order article via Infotrieve]
16.
Winter, C. C.,
Gumperz, J. E.,
Parham, P.,
Long, E. O.,
and Wagtmann, N.
(1998)
J. Immunol.
161,
571-577 17.
Kim, J.,
Chwae, Y. J.,
Kim, M. Y.,
Choi, I. H.,
Park, J. H.,
and Kim, S. J.
(1997)
J. Immunol.
159,
3875-3882[Abstract]
18.
Valés-Gómez, M.,
Reyburn, H. T.,
Erskine, R. A.,
and Strominger, J. L.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
14326-14331 19.
Malnati, M. S.,
Peruzzi, M.,
Parker, K. C.,
Biddison, W. E.,
Ciccone, E.,
Moretta, A.,
and Long, E. O.
(1995)
Science
267,
1016-1018 20.
Rajagopalan, S.,
and Long, E. O.
(1997)
J. Exp. Med.
185,
1523-1528 21.
Mandelboim, O.,
Wilson, S. B.,
Valés-Gómez, M.,
Reyburn, H. T.,
and Strominger, J. L.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
4604-4609 22.
Zappacosta, F.,
Borrego, F.,
Brooks, A. G.,
Parker, K. C.,
and Coligan, J. E.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
6313-6318 23.
Valés-Gómez, M.,
Reyburn, H. T.,
Mandelboim, M.,
and Strominger, J. L.
(1998)
Immunity
9,
337-344[CrossRef][Medline]
[Order article via Infotrieve]
24.
Valés-Gómez, M.,
Reyburn, H. T.,
Mandelboim, M.,
and Strominger, J. L.
(1998)
Immunity
9,
892[CrossRef]
25.
Reid, S. W.,
Smith, K. J.,
Jakobsen, B. K.,
O'Callaghan, C. A.,
Reyburn, H.,
Harlos, K.,
Stuart, D. I.,
McMichael, A. J.,
Bell, J. I.,
and Jones, E. Y.
(1996)
FEBS Lett.
383,
119-123[CrossRef][Medline]
[Order article via Infotrieve]
26.
Garboczi, D. N.,
Hung, D. T.,
and Wiley, D. C.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
3429-3433 27.
Vessey, S. J.,
Barouch, D. H.,
McAdam, S. N.,
Tussey, L. G.,
Davenport, M. A.,
O'Callaghan, C. A.,
Bell, J. I.,
McMichael, A. J.,
and Jakobsen, B. K.
(1997)
Eur. J. Immunol.
27,
879-885[Medline]
[Order article via Infotrieve]
28.
Wyer, J. R.,
Willcox, B. E.,
Gao, G. F.,
Gerth, U. C.,
Davis, S. J.,
Bell, J. I.,
van der Merwe, P. A.,
and Jakobsen, B. K.
(1999)
Immunity
10,
219-225[CrossRef][Medline]
[Order article via Infotrieve]
29.
Yoo, S. H.,
and Lewis, M. S.
(1995)
Biochemistry
34,
632-638[CrossRef][Medline]
[Order article via Infotrieve]
30.
Maenaka, K.,
Juji, T.,
Stuart, D. I.,
and Jones, E. Y.
(1999)
Structure
7,
391-398[Medline]
[Order article via Infotrieve]
31.
Karlsson, R.,
and Falt, A.
(1997)
J. Immunol. Methods
200,
121-133[CrossRef][Medline]
[Order article via Infotrieve]
32.
Willcox, B. E.,
Gao, G. F.,
Wyer, J. R.,
Ladbury, J. E.,
Bell, J. I.,
Jakobsen, B. K.,
and van der Merwe, P. A.
(1999)
Immunity
10,
357-365[CrossRef][Medline]
[Order article via Infotrieve]
33.
Stites, W. E.
(1997)
Chem. Rev.
97,
1233-1250[CrossRef][Medline]
[Order article via Infotrieve]
34.
Fan, Q. R.,
Mosyak, L.,
Winter, C. C.,
Wagtmann, N.,
Long, E. O.,
and Wiley, D. C.
(1997)
Nature
389,
96-100[CrossRef][Medline]
[Order article via Infotrieve]
35.
Dustin, M. L.,
Golan, D. E.,
Zhu, D. M.,
Miller, J. M.,
Meier, W.,
Davies, E. A.,
and van der Merwe, P. A.
(1997)
J. Biol. Chem.
272,
30889-30898 36.
Davis, M. M.,
Boniface, J. J.,
Reich, Z.,
Lyons, D.,
Hampl, J.,
Arden, B.,
and Chien, Y.
(1998)
Annu. Rev. Immunol.
16,
523-544[CrossRef][Medline]
[Order article via Infotrieve]
37.
Garcia, K. C.,
Degano, M.,
Pease, L. R.,
Huang, M.,
Peterson, P. A.,
Teyton, L.,
and Wilson, I. A.
(1998)
Science
279,
1166-1172 38.
van der Merwe, P. A.,
Barclay, A. N.,
Mason, D. W.,
Davies, E. A.,
Morgan, B. P.,
Tone, M.,
Krishnam, A. K. C.,
Ianelli, C.,
and Davis, S. J.
(1994)
Biochemistry
33,
10149-10160[CrossRef][Medline]
[Order article via Infotrieve]
39.
Davis, S. J.,
Ikemizu, S.,
Wild, M. K.,
and van der Merwe, P. A.
(1998)
Immunol. Rev.
163,
217-236[CrossRef][Medline]
[Order article via Infotrieve]
40.
Brown, M. H.,
Boles, K.,
van der Merwe, P. A.,
Kumar, V.,
Mathew, P. A.,
and Barclay, A. N.
(1998)
J. Exp. Med.
188,
2083-2090 41.
van der Merwe, P. A.,
Bodian, D. L.,
Daenke, S.,
Linsley, P.,
and Davis, S. J.
(1997)
J. Exp. Med.
185,
393-403
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
G. Alter, S. Rihn, H. Streeck, N. Teigen, A. Piechocka-Trocha, K. Moss, K. Cohen, A. Meier, F. Pereyra, B. Walker, et al. Ligand-Independent Exhaustion of Killer Immunoglobulin-Like Receptor-Positive CD8+ T Cells in Human Immunodeficiency Virus Type 1 Infection J. Virol., October 1, 2008; 82(19): 9668 - 9677. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS J. Leukoc. Biol., July 1, 2008; 84(1): 1 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tabata, K. Kuroki, J. Wang, M. Kajikawa, I. Shiratori, D. Kohda, H. Arase, and K. Maenaka Biophysical Characterization of O-Glycosylated CD99 Recognition by Paired Ig-like Type 2 Receptors J. Biol. Chem., April 4, 2008; 283(14): 8893 - 8901. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Moesta, P. J. Norman, M. Yawata, N. Yawata, M. Gleimer, and P. Parham Synergistic Polymorphism at Two Positions Distal to the Ligand-Binding Site Makes KIR2DL2 a Stronger Receptor for HLA-C Than KIR2DL3 J. Immunol., March 15, 2008; 180(6): 3969 - 3979. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Patel, S. E. Harding, A. Ebringerova, M. Deszczynski, Z. Hromadkova, A. Togola, B. S. Paulsen, G. A. Morris, and A. J. Rowe Weak Self-Association in a Carbohydrate System Biophys. J., August 1, 2007; 93(3): 741 - 749. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Lebbink, T. de Ruiter, J. Adelmeijer, A. B. Brenkman, J. M. van Helvoort, M. Koch, R. W. Farndale, T. Lisman, A. Sonnenberg, P. J. Lenting, et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1 J. Exp. Med., June 12, 2006; 203(6): 1419 - 1425. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.A. Richman, S.J. Healan, K.S. Weber, D.L. Donermeyer, M.L. Dossett, P.D. Greenberg, P.M. Allen, and D.M. Kranz Development of a novel strategy for engineering high-affinity proteins by yeast display Protein Eng. Des. Sel., June 1, 2006; 19(6): 255 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Boyton, J. Smith, R. Ward, M. Jones, L. Ozerovitch, R. Wilson, M. Rose, J. Trowsdale, and D. M. Altmann HLA-C and Killer Cell Immunoglobulin-like Receptor Genes in Idiopathic Bronchiectasis Am. J. Respir. Crit. Care Med., February 1, 2006; 173(3): 327 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Stewart, F. Laugier-Anfossi, F. Vely, X. Saulquin, J. Riedmuller, A. Tisserant, L. Gauthier, F. Romagne, G. Ferracci, F. A. Arosa, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors PNAS, September 13, 2005; 102(37): 13224 - 13229. [Abstract] [Full Text] [PDF] |
||||